Aegon NV increased its share buyback authorization to €350 million following stronger-than-expected first-half results, despite a decline in free cash flow and a drop in its solvency ratio.
The Dutch insurer reported a first-half operating result of €804 million, exceeding the €750 million consensus estimate compiled by Reuters. Operating capital generation rose to €416 million, aided by €34 million in one-off items and favorable variances in financial assets and persistency, though it remained below the €415 million median forecast. Net profit edged up to €608 million from €606 million a year earlier, while free cash flow fell to €392 million from €442 million, missing the €415 million consensus.
Cash capital at the holding company rose to €1.66 billion, above both the €1.62 billion consensus and its operating range, enabling an expanded buyback intended to reduce the balance to around €1.0 billion by year-end. The enlarged program follows the company’s previously announced £2 billion sale of its UK operations to Standard Life, expected to close by the end of 2026.
Aegon’s group solvency ratio declined to 169% as of June 30, 2026, down from 184% at the end of 2025, while its U.S. risk-based capital ratio eased to 420% from 424%, remaining above its 400% operating level. The insurer declared an interim dividend of €0.21 per common share for 2026, matching the consensus and marking an 11% increase over the 2025 interim payout.
U.S. operations contributed to growth, with Individual Life sales at Transamerica rising 54% during the period. The World Financial Group distribution network surpassed 100,000 licensed agents. Shares of Aegon fell more than 3% on Thursday after the results were released.
Aegon also confirmed plans to redomicile its headquarters to New York City, with an Extraordinary General Meeting scheduled for October 8, 2026, to seek shareholder approval. CEO Lard Friese’s term was extended to the end of the 2030 annual general meeting, while Will Fuller will assume the roles of President and Chief Operating Officer on January 1, 2027.
Morgan Stanley maintains an equal-weight rating on Aegon with a €7.70 price target, citing adjusted figures that are in line with, if not slightly ahead of, market expectations.
